Market Cap | 213.60B | P/E | 37.80 | EPS this Y | 0.80% | Ern Qtrly Grth | 13.70% |
Income | 6.22B | Forward P/E | 22.40 | EPS next Y | 9.70% | 50D Avg Chg | 5.00% |
Sales | 42.35B | PEG | 4.09 | EPS past 5Y | 9.92% | 200D Avg Chg | 2.00% |
Dividend | N/A | Price/Book | 4.88 | EPS next 5Y | 6.90% | 52W High Chg | -9.00% |
Recommedations | 2.00 | Quick Ratio | 1.24 | Shares Outstanding | 382M | 52W Low Chg | 16.00% |
Insider Own | 0.18% | ROA | 4.83% | Shares Float | 381.14M | Beta | 0.78 |
Inst Own | 90.95% | ROE | 13.53% | Shares Shorted/Prior | 3.99M/3.32M | Price | 553.76 |
Gross Margin | 40.69% | Profit Margin | 14.69% | Avg. Volume | 1,704,174 | Target Price | 653.16 |
Oper. Margin | 17.40% | Earnings Date | Oct 23 | Volume | 1,398,652 | Change | 1.45% |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Evercore ISI Group | Outperform | Oct 1, 24 |
Stephens & Co. | Overweight | Oct 1, 24 |
JP Morgan | Overweight | Sep 20, 24 |
Stifel | Buy | Sep 20, 24 |
RBC Capital | Outperform | Sep 20, 24 |
Morgan Stanley | Overweight | Sep 20, 24 |
B of A Securities | Buy | Sep 16, 24 |
Wells Fargo | Overweight | Aug 27, 24 |
TD Cowen | Buy | Jul 25, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Pettiti Gianluca | Executive Vice Presi.. Executive Vice President | Aug 30 | Sell | 557.77 | 3,000 | 1,673,310 | 17,556 | 08/31/23 |
Pettiti Gianluca | Executive Vice Presi.. Executive Vice President | Aug 30 | Option | 253.99 | 3,000 | 761,970 | 20,556 | 08/31/23 |
CASPER MARC N | Chairman & CEO Chairman & CEO | May 08 | Sell | 541.28 | 11,600 | 6,278,848 | 141,330 | 05/10/23 |
CASPER MARC N | Chairman & CEO Chairman & CEO | May 08 | Option | 157.68 | 11,600 | 1,829,088 | 142,930 | 05/10/23 |
Pettiti Gianluca | Executive Vice Presi.. Executive Vice President | Dec 13 | Option | 210.68 | 4,975 | 1,048,133 | 21,425 | 12/15/22 |
Pettiti Gianluca | Executive Vice Presi.. Executive Vice President | Dec 13 | Sell | 572.98 | 6,975 | 3,996,536 | 14,450 | 12/15/22 |
CASPER MARC N | Chairman & CEO Chairman & CEO | Nov 04 | Option | 129.77 | 18,100 | 2,348,837 | 186,105 | 11/08/22 |
CASPER MARC N | Chairman & CEO Chairman & CEO | Nov 04 | Sell | 491.78 | 18,100 | 8,901,218 | 178,005 | 11/08/22 |
CASPER MARC N | Chairman & CEO Chairman & CEO | Oct 31 | Option | 129.77 | 20,000 | 2,595,400 | 188,005 | 11/02/22 |
CASPER MARC N | Chairman & CEO Chairman & CEO | Oct 31 | Sell | 514.66 | 20,000 | 10,293,200 | 178,005 | 11/02/22 |
Williamson Stephen | Sr. VP and CFO Sr. VP and CFO | Aug 12 | Option | 157.68 | 27,300 | 4,304,664 | 56,244 | 08/16/22 |
Williamson Stephen | Sr. VP and CFO Sr. VP and CFO | Aug 12 | Sell | 602.98 | 27,300 | 16,461,354 | 43,944 | 08/16/22 |
Boxer Michael A | SVP and General Coun.. SVP and General Counsel | Aug 08 | Option | 192.98 | 7,283 | 1,405,473 | 19,681 | 08/10/22 |
Boxer Michael A | SVP and General Coun.. SVP and General Counsel | Aug 08 | Sell | 590.8 | 7,283 | 4,302,796 | 12,398 | 08/10/22 |
Lagarde Michel | Executive Vice Presi.. Executive Vice President & COO | May 26 | Option | 308.28 | 29,794 | 9,184,894 | 28,788 | 05/31/22 |
Lagarde Michel | Executive Vice Presi.. Executive Vice President & COO | May 26 | Sell | 550.77 | 29,794 | 16,409,641 | 15,758 | 05/31/22 |
Lagarde Michel | Executive Vice Presi.. Executive Vice President & COO | May 24 | Option | 237.32 | 22,198 | 5,268,029 | 20,806 | 05/25/22 |
Lagarde Michel | Executive Vice Presi.. Executive Vice President & COO | May 24 | Sell | 545.95 | 22,198 | 12,118,998 | 15,758 | 05/25/22 |
CASPER MARC N | Chairman & CEO Chairman & CEO | May 03 | Sell | 562.59 | 2,181 | 1,227,009 | 183,373 | 05/05/22 |
CASPER MARC N | Chairman & CEO Chairman & CEO | May 03 | Option | 129.77 | 20,000 | 2,595,400 | 193,373 | 05/05/22 |
Spar Debora L | Director Director | May 02 | Sell | 544.358 | 200 | 108,872 | 810 | 05/04/22 |
CASPER MARC N | Chairman & CEO Chairman & CEO | May 02 | Option | 129.77 | 10,000 | 1,297,700 | 193,373 | 05/04/22 |
CASPER MARC N | Chairman & CEO Chairman & CEO | May 02 | Sell | 544.98 | 10,000 | 5,449,800 | 183,373 | 05/04/22 |
MANZI JIM P | Director Director | Feb 14 | Sell | 563.95 | 1,500 | 845,925 | 16,252 | 02/15/22 |
CASPER MARC N | Chairman & CEO Chairman & CEO | Oct 28 | Sell | 484.63 | 20,000 | 9,692,600 | 211,594 | 10/28/20 |